Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program
Go back to Merck Acquires IOmet Pharma and Expands Immuno-Oncology Development Program| Merck & Co. (NYSE: MRK) | Delayed: 146.40 -2.29 (1.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $148.69 | 52 Week High | $65.46 | |||
| Open | $148.17 | 52 Week Low | $47.97 | |||
| Day High | $150.36 | P/E | 99.59 | |||
| Day Low | $146.09 | EPS | $1.47 | |||
| Volume | 1,184,100 | |||||
